- Home
- FLNC vs ZLAB Comparison
FLNC vs ZLAB Comparison
Compare FLNC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- ZLAB
- Stock Information
- Founded
- FLNC 2018
- ZLAB 2013
- Country
- FLNC United States
- ZLAB China
- Employees
- FLNC N/A
- ZLAB N/A
- Industry
- FLNC Industrial Machinery/Components
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- ZLAB Health Care
- Exchange
- FLNC Nasdaq
- ZLAB Nasdaq
- Market Cap
- FLNC 2.4B
- ZLAB 1.8B
- IPO Year
- FLNC 2021
- ZLAB 2017
- Fundamental
- Price
- FLNC $22.01
- ZLAB $31.24
- Analyst Decision
- FLNC Buy
- ZLAB Strong Buy
- Analyst Count
- FLNC 17
- ZLAB 4
- Target Price
- FLNC $27.35
- ZLAB $52.50
- AVG Volume (30 Days)
- FLNC 1.3M
- ZLAB 976.3K
- Earning Date
- FLNC 11-26-2024
- ZLAB 11-12-2024
- Dividend Yield
- FLNC N/A
- ZLAB N/A
- EPS Growth
- FLNC N/A
- ZLAB N/A
- EPS
- FLNC N/A
- ZLAB N/A
- Revenue
- FLNC $2,143,395,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- FLNC $27.28
- ZLAB $48.34
- Revenue Next Year
- FLNC $44.10
- ZLAB $47.12
- P/E Ratio
- FLNC N/A
- ZLAB N/A
- Revenue Growth
- FLNC 7.87
- ZLAB 28.16
- 52 Week Low
- FLNC $12.74
- ZLAB $13.48
- 52 Week High
- FLNC $27.80
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- FLNC 53.21
- ZLAB 70.41
- Support Level
- FLNC $20.00
- ZLAB $31.52
- Resistance Level
- FLNC $21.65
- ZLAB $36.60
- Average True Range (ATR)
- FLNC 0.96
- ZLAB 1.36
- MACD
- FLNC -0.08
- ZLAB 0.34
- Stochastic Oscillator
- FLNC 65.79
- ZLAB 58.60
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.